

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

04 Jun 2026

### Effect of vitamin D supplementation versus placebo on hypertension in patients with vitamin D deficiency: a double blind randomized clinical trial

#### Protocol summary

##### Summary

Objectives: To assess the effect of vitamin D supplementation versus placebo on hypertension in patients with vitamin D deficiency. Design: a double blind randomized clinical trial. Setting and conduct: The eligible patients with vitamin D deficiency who will refer to Farshchian Hospital during the study period will be enrolled into the trial. Inclusion criteria: Age of 18 to 75 years; systolic blood pressure equal to or greater than 140 mmHg or diastolic blood pressure equal to or greater than 90 mmHg in tow times; vitamin D deficiency. Exclusion criteria: Pregnancy; secondary hypertension; renal failure; a history of using vitamin D or calcium during the last three months; using Thiazide-type diuretics. Intervention group: Routine anti-hypertensive drugs plus gelatin tablet vitamin D (Calciferol) based on Vitamin D serum level (50,000 U once a week oral in subjects with Vitamin D serum level less than 20 ngr/mL and 1000 U in subjects with serum level between 20 to 30 ngr/mL) for 2 months Control group: Routine anti-hypertensive drugs plus gelatin tablet placebo once a week for 2 months. Primary outcome: Measuring systolic and diastolic blood pressure in sitting position from the right hand using mercury sphygmomanometer before intervention and then monthly for 2 months. Secondary outcome: Measuring serum Calciferol before intervention and then monthly for 2 months through laboratory test. Randomization: The patients will be randomly assigned to intervention and control groups using block randomization. Blinding: Patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. The analyzer will be unaware of the type of interventions. Therefore, the trial will be run as double blind.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201703129014N151**  
Registration date: **2017-03-12, 1395/12/22**  
Registration timing: **prospective**

Last update:

Update count: **0**

##### Registration date

2017-03-12, 1395/12/22

##### Registrant information

##### Name

Jalal Poorolajal

##### Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan  
University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 81 1838 0090

##### Email address

poorolajal@umsha.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice-chancellor for Research the Technology, Hamadan  
University of Medical Sciences

##### Expected recruitment start date

2017-04-04, 1396/01/15

##### Expected recruitment end date

2018-03-20, 1396/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
Effect of vitamin D supplementation versus placebo on hypertension in patients with vitamin D deficiency: a double blind randomized clinical trial

**Public title**  
Effect of vitamin D supplementation versus placebo on hypertension in patients with vitamin D deficiency

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
Inclusion criteria: Age of 18 to 75 years; systolic blood pressure equal to or greater than 140 mmHg or diastolic blood pressure equal to or greater than 90 mmHg in two times; vitamin D deficiency. Exclusion criteria: Pregnancy; secondary hypertension; renal failure; a history of using vitamin D or calcium during the last three months; using Thiazide-type diuretics.

**Age**  
From **18 years** old to **75 years** old

**Gender**  
Both

**Phase**  
2

**Groups that have been masked**  
*No information*

**Sample size**  
Target sample size: **208**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**  
Randomization: The patients will be randomly assigned to intervention and control groups using block randomization. Blinding: Patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. The analyzer will be unaware of the type of interventions. Therefore, the trial will be run as double blind.

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Hamadan University of Medical

Sciences

**Street address**  
Vice-chancellor for Research the Technology,  
Hamadan University of Medical Sciences, Shahid  
Fahmideh Ave

**City**  
Hamadan

**Postal code**  
6517838695

**Approval date**  
2016-12-10, 1395/09/20

**Ethics committee reference number**  
IR.UMSHA.REC.1395.393

## Health conditions studied

### 1

#### Description of health condition studied

Vitamin D deficiency

#### ICD-10 code

E55

#### ICD-10 code description

Vitamin D deficiency

## Primary outcomes

### 1

#### Description

Measuring systolic and diastolic blood pressure

#### Timepoint

before intervention and then monthly for 2 months

#### Method of measurement

in sitting position from the right hand using mercury sphygmomanometer

## Secondary outcomes

### 1

#### Description

Measuring serum Calciferol

#### Timepoint

before intervention and then monthly for 2 months

#### Method of measurement

through laboratory test

## Intervention groups

### 1

#### Description

Intervention group: Routine anti-hypertensive drugs plus gelatin tablet vitamin D (Calciferol) based on Vitamin D serum level (50,000 U once a week oral in subjects with Vitamin D serum level less than 20 ngr/mL and 1000 U in subjects with serum level between 20 to 30 ngr/mL) for 2 months

#### Category

Treatment - Drugs

## 2

### Description

Control group: Routine anti-hypertensive drugs plus gelatin tablet placebo once a week for 2 months.

### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Farshchian Hospital

##### Full name of responsible person

Dr Vida Sheikh

##### Street address

Farshchian Heart Hospital, Shahid Fahmideh Ave.

##### City

Hamadan

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Vice-chancellor for Research the Technology,  
Hamadan University of Medical Sciences

##### Full name of responsible person

Dr Saeid Bashirian

##### Street address

Hamadan University of Medical Sciences, Shahid  
Fahmideh Ave

##### City

Hamadan

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Vice-chancellor for Research the Technology, Hamadan  
University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

*empty*

#### Domestic or foreign origin

*empty*

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

*empty*

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Farshchian Heart Hospital

#### Full name of responsible person

Dr Vida Sheikh

#### Position

Nephrologist

#### Other areas of specialty/work

#### Street address

Farshchian Heart Hospital, Shahid Fahmideh Ave.

#### City

Hamadan

#### Postal code

#### Phone

+98 81 3838 1740

#### Fax

#### Email

vsh\_57072@yahoo.com

#### Web page address

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Farshchian Heart Hospital

#### Full name of responsible person

Dr Vida Sheikh

#### Position

Nephrologist

#### Other areas of specialty/work

#### Street address

Farshchian Heart Hospital, Shahid Fahmideh Ave.

#### City

Hamadan

#### Postal code

#### Phone

+98 81 3838 1740

#### Fax

#### Email

vsh\_57072@yahoo.com

#### Web page address

## Person responsible for updating data

### Contact

#### Name of organization / entity

Department of Epidemiology

#### Full name of responsible person

Dr Jalal Poorolajal

#### Position

Associate Professor

#### Other areas of specialty/work

#### Street address

School of Public Health, Hamadan University of  
Medical Sciences, Shahid Fahmideh Ave

#### City

Hamadan

#### Postal code

6517838695

#### Phone

+98 81 3838 0090

#### Fax

#### Email

poorolajal@umsha.ac.ir

**Web page address**

*empty*

## **Sharing plan**

**Informed Consent Form**

*empty*

**Deidentified Individual Participant Data Set (IPD)**

**Clinical Study Report**

*empty*

*empty*

**Study Protocol**

**Analytic Code**

*empty*

*empty*

**Data Dictionary**

**Statistical Analysis Plan**

*empty*